By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The Life Science Nation (LSN) team is preparing to welcome the global life science ecosystem to Boston for the upcoming RESI conference this September. With an engaging lineup of investor panels, workshops, and the Innovator’s Pitch Challenge, founders and CEOs will have the opportunity to connect directly with investors while gaining tactical insights into fundraising and partnership strategies.
The RESI Boston program features seven investor panels spanning impact investing, mental health, oncology, diagnostics, family offices, corporate venture capital, and big pharma partnerships. These panels bring together a diverse group of experts—from venture funds and strategic investors to philanthropic groups and family offices—each offering unique perspectives on how they evaluate life science and healthcare opportunities.
Each 50-minute session will provide a candid look at what drives investor interest in early-stage ventures, what makes a company stand out in competitive landscapes, and how founders can build lasting relationships with the capital sources they need.
RESI Boston is not just about learning—it’s about engagement. Panelists will share their perspectives on industry landscapes, while also fielding questions and offering insights that directly address the challenges entrepreneurs face. These conversations are intended to bridge the gap between companies and capital providers, fostering the connections that fuel healthcare innovation.
Below is the schedule of investor panels at RESI Boston this September:
 John Abeles General Partner Northlea Partners |
 Marc Appel Managing Partner Pacific Bridge NY |
 Jonathan Behr Partner Dementia Discovery Fund |
 David Berry Managing Partner Averin Capital |
 Hyelim Cho Sr. Director, BD and Alliance Management RayzeBio (a Bristol Myers Squibb company) |
 Alex de Winter Vice President of New Ventures Danaher Corporation |
 Yizhen Dong Managing Partner Raise Health |
 David Fogel Member of Screening & Due Diligence Committees Mass Medical Angels |
 Eric Furfine CEO & CSO Mosaic Biosciences |
 Navin Govind Partner Evidence Ventures |
 Andres Hurtado-Lorenzo SVP, Translational Research & IBD Ventures Crohn's and Colitis Foundation |
 Anula Jayasuriya Co-Founder and Partner Kidron Capital |
 Arianne Kidder Partner Seae Ventures |
 Claire Leurent Managing Director AbbVie Ventures |
 Ron Levin Managing Partner Alumni Ventures |
 Vivian Li Investor K2 Venture Partners |
 Michael Loftus Director PoC Capital |
 Nune Martiros Senior Associate Paladin Capital Group |
 Jeffrey Moore President MP Healthcare Venture Management (MPH) |
 Chris Murray Principal MVM Life Science Partners |
 Nikhil Mutyal Head of Search and Evaluation, Respiratory and Immunology AstraZeneca |
 Komeil Nasrollahi Sr. Director Innovation & Venture Partnerships Siemens Healthineers |
 Stephanie Oestreich Managing Director Myeloma Investment Fund |
 Armin Rump Director of Global BD Otsuka Pharmaceutical Co., Ltd. |
 Jeremy Sohn Managing Partner P74 Ventures |
 Mike Thomas Managing Partner Bold Brain Capital |
 John Tremblay Investor Launchpad Venture Group |
 Chensu Wang Investment Manager Yonjin Venture |
 Jenny Wang Director, Search & Evaluation, Oncology AbbVie |
 Tyler Wanke Investor Wanke Family Office |
Whether you are developing novel therapeutics, diagnostics, medical devices, or digital health solutions, the investor panels at RESI Boston will deliver the knowledge and networking opportunities to help you advance your fundraising journey.
Next Phase Newsletter 
Leave a comment